On this basis, we propose the presence of glutamine to characterize bone marrow sites where BCR/Abl-negative, TKi-resistant LSCs of CML are hosted, i.e., where MRD is maintained. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.